ID   GATM_HUMAN              Reviewed;         423 AA.
AC   P50440; B4DH99; B4DPI3; Q53EQ4;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Glycine amidinotransferase, mitochondrial;
DE            EC=2.1.4.1 {ECO:0000269|PubMed:27233232, ECO:0000269|PubMed:3800397};
DE   AltName: Full=L-arginine:glycine amidinotransferase;
DE   AltName: Full=Transamidinase;
DE   Flags: Precursor;
GN   Name=GATM; Synonyms=AGAT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=8313955; DOI=10.1016/0014-5793(94)80394-3;
RA   Humm A., Huber R., Mann K.;
RT   "The amino acid sequences of human and pig L-arginine:glycine
RT   amidinotransferase.";
RL   FEBS Lett. 339:101-107(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RA   Austruy E., Belley L., Millasot P., Junien C., Jeanpierre C.;
RT   "Characterization of the human cDNA with partial homology with the
RT   gamma subunit of sodium potassium ATPase of rat, mouse, rabbit and
RT   sheep.";
RL   Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Brain, and Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   HIS-110.
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RX   PubMed=3800397; DOI=10.1016/0003-9861(86)90385-1;
RA   Gross M.D., Eggen M.A., Simon A.M., Van Pilsum J.F.;
RT   "The purification and characterization of human kidney L-
RT   arginine:glycine amidinotransferase.";
RL   Arch. Biochem. Biophys. 251:747-755(1986).
RN   [8]
RP   ACTIVE SITE CYS-407.
RX   PubMed=9148748; DOI=10.1042/bj3220771;
RA   Humm A., Fritsche E., Mann K., Goehl U., Huber R.;
RT   "Recombinant expression and isolation of human L-arginine:glycine
RT   amidinotransferase and identification of its active-site cysteine
RT   residue.";
RL   Biochem. J. 322:771-776(1997).
RN   [9]
RP   REVIEW.
RX   PubMed=9165070;
RA   Humm A., Fritsche E., Steinbacher S.;
RT   "Structure and reaction mechanism of L-arginine:glycine
RT   amidinotransferase.";
RL   Biol. Chem. 378:193-197(1997).
RN   [10]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=16820567; DOI=10.1161/CIRCULATIONAHA.105.000448;
RA   Cullen M.E., Yuen A.H., Felkin L.E., Smolenski R.T., Hall J.L.,
RA   Grindle S., Miller L.W., Birks E.J., Yacoub M.H., Barton P.J.;
RT   "Myocardial expression of the arginine:glycine amidinotransferase gene
RT   is elevated in heart failure and normalized after recovery: potential
RT   implications for local creatine synthesis.";
RL   Circulation 114:I16-I20(2006).
RN   [11]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=16125225; DOI=10.1016/j.placenta.2005.07.004;
RA   McMinn J., Wei M., Schupf N., Cusmai J., Johnson E.B., Smith A.C.,
RA   Weksberg R., Thaker H.M., Tycko B.;
RT   "Unbalanced placental expression of imprinted genes in human
RT   intrauterine growth restriction.";
RL   Placenta 27:540-549(2006).
RN   [12]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16614068; DOI=10.1073/pnas.0511031103;
RA   Monk D., Arnaud P., Apostolidou S., Hills F.A., Kelsey G., Stanier P.,
RA   Feil R., Moore G.E.;
RT   "Limited evolutionary conservation of imprinting in the human
RT   placenta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6623-6628(2006).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-385, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   INVOLVEMENT IN CCDS3.
RX   PubMed=20682460; DOI=10.1016/j.ymgme.2010.06.021;
RA   Edvardson S., Korman S.H., Livne A., Shaag A., Saada A.,
RA   Nalbandian R., Allouche-Arnon H., Gomori J.M., Katz-Brull R.;
RT   "l-arginine:glycine amidinotransferase (AGAT) deficiency: clinical
RT   presentation and response to treatment in two patients with a novel
RT   mutation.";
RL   Mol. Genet. Metab. 101:228-232(2010).
RN   [15]
RP   INVOLVEMENT IN CCDS3.
RX   PubMed=22386973; DOI=10.1016/j.ymgme.2012.01.017;
RA   Ndika J.D., Johnston K., Barkovich J.A., Wirt M.D., O'Neill P.,
RA   Betsalel O.T., Jakobs C., Salomons G.S.;
RT   "Developmental progress and creatine restoration upon long-term
RT   creatine supplementation of a patient with arginine:glycine
RT   amidinotransferase deficiency.";
RL   Mol. Genet. Metab. 106:48-54(2012).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-49, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 38-423.
RC   TISSUE=Kidney;
RX   PubMed=9218780; DOI=10.1093/emboj/16.12.3373;
RA   Humm A., Fritsche E., Steinbacher S., Huber R.;
RT   "Crystal structure and mechanism of human L-arginine:glycine
RT   amidinotransferase: a mitochondrial enzyme involved in creatine
RT   biosynthesis.";
RL   EMBO J. 16:3373-3385(1997).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.36 ANGSTROMS) OF MUTANTS ASN-170; ASN-254 AND
RP   SER-407, BIOPHYSICOCHEMICAL PROPERTIES, REACTION MECHANISM, AND
RP   MUTAGENESIS OF ASP-170; GLU-233; ASP-254; HIS-303; ASP-305; ARG-322;
RP   SER-355; CYS-407 AND CYS-410.
RX   PubMed=9266688; DOI=10.1111/j.1432-1033.1997.00483.x;
RA   Fritsche E., Humm A., Huber R.;
RT   "Substrate binding and catalysis by L-arginine:glycine
RT   amidinotransferase -- a mutagenesis and crystallographic study.";
RL   Eur. J. Biochem. 247:483-490(1997).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 38-423.
RX   PubMed=9915841; DOI=10.1074/jbc.274.5.3026;
RA   Fritsche E., Humm A., Huber R.;
RT   "The ligand-induced structural changes of human L-arginine:glycine
RT   amidinotransferase. A mutational and crystallographic study.";
RL   J. Biol. Chem. 274:3026-3032(1999).
RN   [21]
RP   INVOLVEMENT IN CCDS3.
RX   PubMed=11555793; DOI=10.1086/323765;
RA   Item C.B., Stockler-Ipsiroglu S., Stromberger C., Muhl A.,
RA   Alessandri M.G., Bianchi M.C., Tosetti M., Fornai F., Cioni G.;
RT   "Arginine:glycine amidinotransferase deficiency: the third inborn
RT   error of creatine metabolism in humans.";
RL   Am. J. Hum. Genet. 69:1127-1133(2001).
RN   [22]
RP   VARIANTS CCDS3 GLN-413 AND TRP-413.
RX   PubMed=23660394; DOI=10.1016/j.ymgme.2013.04.006;
RA   Comeaux M.S., Wang J., Wang G., Kleppe S., Zhang V.W., Schmitt E.S.,
RA   Craigen W.J., Renaud D., Sun Q., Wong L.J.;
RT   "Biochemical, molecular, and clinical diagnoses of patients with
RT   cerebral creatine deficiency syndromes.";
RL   Mol. Genet. Metab. 109:260-268(2013).
RN   [23]
RP   VARIANT CCDS3 SER-203.
RX   PubMed=23770102; DOI=10.1016/j.nmd.2013.04.011;
RA   Nouioua S., Cheillan D., Zaouidi S., Salomons G.S., Amedjout N.,
RA   Kessaci F., Boulahdour N., Hamadouche T., Tazir M.;
RT   "Creatine deficiency syndrome. A treatable myopathy due to arginine-
RT   glycine amidinotransferase (AGAT) deficiency.";
RL   Neuromuscul. Disord. 23:670-674(2013).
RN   [24]
RP   VARIANTS CCDS3 PRO-185; SER-203 AND TRP-413.
RX   PubMed=26490222; DOI=10.1016/j.ymgme.2015.10.003;
RA   Stockler-Ipsiroglu S., Apatean D., Battini R., DeBrosse S.,
RA   Dessoffy K., Edvardson S., Eichler F., Johnston K., Koeller D.M.,
RA   Nouioua S., Tazir M., Verma A., Dowling M.D., Wierenga K.J.,
RA   Wierenga A.M., Zhang V., Wong L.J.;
RT   "Arginine:glycine amidinotransferase (AGAT) deficiency: Clinical
RT   features and long term outcomes in 16 patients diagnosed worldwide.";
RL   Mol. Genet. Metab. 116:252-259(2015).
RN   [25]
RP   VARIANTS CCDS3 GLN-23; VAL-93; ASN-102; LEU-105; LYS-181; PRO-185;
RP   CYS-189; SER-203; THR-208; HIS-282; VAL-329; LEU-346; TRP-413; GLN-413
RP   AND GLN-415, CHARACTERIZATION OF VARIANTS CCDS3 GLN-23; VAL-93;
RP   ASN-102; LEU-105; LYS-181; PRO-185; CYS-189; SER-203; THR-208;
RP   HIS-282; VAL-329; LEU-346; TRP-413; GLN-413 AND GLN-415, VARIANTS
RP   CYS-231 AND GLY-234, CHARACTERIZATION OF VARIANTS CYS-231 AND GLY-234,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=27233232; DOI=10.1002/humu.23018;
RA   DesRoches C.L., Bruun T., Wang P., Marshall C.R.,
RA   Mercimek-Mahmutoglu S.;
RT   "Arginine-Glycine Amidinotransferase Deficiency and Functional
RT   Characterization of Missense Variants in GATM.";
RL   Hum. Mutat. 37:926-932(2016).
CC   -!- FUNCTION: Catalyzes the biosynthesis of guanidinoacetate, the
CC       immediate precursor of creatine. Creatine plays a vital role in
CC       energy metabolism in muscle tissues. May play a role in embryonic
CC       and central nervous system development. May be involved in the
CC       response to heart failure by elevating local creatine synthesis.
CC       {ECO:0000269|PubMed:16125225, ECO:0000269|PubMed:16614068,
CC       ECO:0000269|PubMed:16820567}.
CC   -!- CATALYTIC ACTIVITY: L-arginine + glycine = L-ornithine +
CC       guanidinoacetate. {ECO:0000269|PubMed:27233232,
CC       ECO:0000269|PubMed:3800397}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.0 uM for arginine {ECO:0000269|PubMed:3800397,
CC         ECO:0000269|PubMed:9266688};
CC         KM=3.0 uM for glycine {ECO:0000269|PubMed:3800397,
CC         ECO:0000269|PubMed:9266688};
CC         Vmax=0.44 umol/min/mg enzyme {ECO:0000269|PubMed:3800397,
CC         ECO:0000269|PubMed:9266688};
CC   -!- PATHWAY: Amine and polyamine biosynthesis; creatine biosynthesis;
CC       creatine from L-arginine and glycine: step 1/2.
CC   -!- SUBUNIT: Homodimer. There is an equilibrium between the monomeric
CC       and dimeric forms, shifted towards the side of the monomer.
CC       {ECO:0000269|PubMed:3800397}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Mitochondrion inner membrane;
CC       Peripheral membrane protein; Intermembrane side. Note=Probably
CC       attached to the outer side of the inner membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Mitochondrial;
CC         IsoId=P50440-1; Sequence=Displayed;
CC       Name=2; Synonyms=Cytoplasmic;
CC         IsoId=P50440-2; Sequence=VSP_000235;
CC       Name=3;
CC         IsoId=P50440-3; Sequence=VSP_039871;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, heart, kidney, liver,
CC       lung, salivary gland and skeletal muscle tissue, with the highest
CC       expression in kidney. Biallelically expressed in placenta and
CC       fetal tissues. {ECO:0000269|PubMed:16125225,
CC       ECO:0000269|PubMed:16614068, ECO:0000269|PubMed:16820567}.
CC   -!- INDUCTION: Expression is elevated in the myocardium during heart
CC       failure, and decreased in inter-uterine growth restriction (IUGR)-
CC       associated placenta. {ECO:0000269|PubMed:16125225,
CC       ECO:0000269|PubMed:16820567}.
CC   -!- DOMAIN: One chain folds into a compact single domain composed of
CC       repeating units, five beta-beta-alpha-beta modules, which surround
CC       the central active site.
CC   -!- DISEASE: Cerebral creatine deficiency syndrome 3 (CCDS3)
CC       [MIM:612718]: An autosomal recessive disorder characterized by
CC       developmental delay/regression, mental retardation, severe
CC       disturbance of expressive and cognitive speech, and severe
CC       depletion of creatine/phosphocreatine in the brain. Most patients
CC       develop a myopathy characterized by muscle weakness and atrophy
CC       later in life. {ECO:0000269|PubMed:11555793,
CC       ECO:0000269|PubMed:20682460, ECO:0000269|PubMed:22386973,
CC       ECO:0000269|PubMed:23660394, ECO:0000269|PubMed:23770102,
CC       ECO:0000269|PubMed:26490222, ECO:0000269|PubMed:27233232}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the amidinotransferase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG60595.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S68805; AAB29892.1; -; mRNA.
DR   EMBL; X86401; CAA60153.1; -; mRNA.
DR   EMBL; AK294995; BAG58060.1; -; mRNA.
DR   EMBL; AK298350; BAG60595.1; ALT_INIT; mRNA.
DR   EMBL; AK223585; BAD97305.1; -; mRNA.
DR   EMBL; AC025580; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004141; AAH04141.1; -; mRNA.
DR   CCDS; CCDS10122.1; -. [P50440-1]
DR   PIR; S41734; S41734.
DR   PIR; S54161; S54161.
DR   RefSeq; NP_001473.1; NM_001482.2. [P50440-1]
DR   UniGene; Hs.560354; -.
DR   UniGene; Hs.729565; -.
DR   UniGene; Hs.75335; -.
DR   PDB; 1JDW; X-ray; 1.90 A; A=1-423.
DR   PDB; 1JDX; X-ray; 2.40 A; A=38-423.
DR   PDB; 2JDW; X-ray; 2.10 A; A=1-423.
DR   PDB; 2JDX; X-ray; 2.90 A; A=38-423.
DR   PDB; 3JDW; X-ray; 2.40 A; A=1-423.
DR   PDB; 4JDW; X-ray; 2.50 A; A=1-423.
DR   PDB; 5JDW; X-ray; 2.60 A; A=38-423.
DR   PDB; 6JDW; X-ray; 2.50 A; A=38-423.
DR   PDB; 7JDW; X-ray; 2.37 A; A=38-423.
DR   PDB; 8JDW; X-ray; 2.30 A; A=38-423.
DR   PDB; 9JDW; X-ray; 2.50 A; A=38-423.
DR   PDBsum; 1JDW; -.
DR   PDBsum; 1JDX; -.
DR   PDBsum; 2JDW; -.
DR   PDBsum; 2JDX; -.
DR   PDBsum; 3JDW; -.
DR   PDBsum; 4JDW; -.
DR   PDBsum; 5JDW; -.
DR   PDBsum; 6JDW; -.
DR   PDBsum; 7JDW; -.
DR   PDBsum; 8JDW; -.
DR   PDBsum; 9JDW; -.
DR   DisProt; DP00099; -.
DR   ProteinModelPortal; P50440; -.
DR   SMR; P50440; -.
DR   BioGrid; 108898; 3.
DR   IntAct; P50440; 7.
DR   STRING; 9606.ENSP00000379895; -.
DR   DrugBank; DB04454; Alpha-Aminobutyric Acid.
DR   DrugBank; DB02068; Delta-Amino Valeric Acid.
DR   DrugBank; DB02530; Gamma(Amino)-Butyric Acid.
DR   DrugBank; DB00145; Glycine.
DR   DrugBank; DB00129; L-Ornithine.
DR   DrugBank; DB04185; Norvaline.
DR   iPTMnet; P50440; -.
DR   PhosphoSitePlus; P50440; -.
DR   BioMuta; GATM; -.
DR   DMDM; 1730201; -.
DR   REPRODUCTION-2DPAGE; IPI00032103; -.
DR   MaxQB; P50440; -.
DR   PaxDb; P50440; -.
DR   PeptideAtlas; P50440; -.
DR   PRIDE; P50440; -.
DR   DNASU; 2628; -.
DR   Ensembl; ENST00000396659; ENSP00000379895; ENSG00000171766. [P50440-1]
DR   Ensembl; ENST00000558336; ENSP00000454008; ENSG00000171766. [P50440-3]
DR   GeneID; 2628; -.
DR   KEGG; hsa:2628; -.
DR   UCSC; uc001zvc.4; human. [P50440-1]
DR   CTD; 2628; -.
DR   DisGeNET; 2628; -.
DR   GeneCards; GATM; -.
DR   GeneReviews; GATM; -.
DR   HGNC; HGNC:4175; GATM.
DR   HPA; HPA026077; -.
DR   MalaCards; GATM; -.
DR   MIM; 602360; gene.
DR   MIM; 612718; phenotype.
DR   neXtProt; NX_P50440; -.
DR   OpenTargets; ENSG00000171766; -.
DR   Orphanet; 35704; Arginine:glycine amidinotransferase deficiency.
DR   PharmGKB; PA28590; -.
DR   eggNOG; ENOG410IFBR; Eukaryota.
DR   eggNOG; ENOG410Y45M; LUCA.
DR   GeneTree; ENSGT00390000011613; -.
DR   HOGENOM; HOG000231593; -.
DR   HOVERGEN; HBG002492; -.
DR   InParanoid; P50440; -.
DR   KO; K00613; -.
DR   OMA; RPCHQID; -.
DR   OrthoDB; EOG091G07LX; -.
DR   PhylomeDB; P50440; -.
DR   TreeFam; TF300256; -.
DR   BioCyc; MetaCyc:HS10376-MONOMER; -.
DR   BRENDA; 2.1.4.1; 2681.
DR   Reactome; R-HSA-71288; Creatine metabolism.
DR   UniPathway; UPA00104; UER00579.
DR   ChiTaRS; GATM; human.
DR   EvolutionaryTrace; P50440; -.
DR   GeneWiki; GATM_(gene); -.
DR   GenomeRNAi; 2628; -.
DR   PRO; PR:P50440; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000171766; -.
DR   CleanEx; HS_GATM; -.
DR   ExpressionAtlas; P50440; baseline and differential.
DR   Genevisible; P50440; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; IDA:MGI.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0015068; F:glycine amidinotransferase activity; IDA:UniProtKB.
DR   GO; GO:0006601; P:creatine biosynthetic process; IDA:MGI.
DR   GO; GO:0006600; P:creatine metabolic process; IMP:CAFA.
DR   GO; GO:0007611; P:learning or memory; IMP:CAFA.
DR   GO; GO:0007275; P:multicellular organism development; IMP:CAFA.
DR   GO; GO:0014889; P:muscle atrophy; IMP:CAFA.
DR   InterPro; IPR033195; AmidinoTrfase.
DR   PANTHER; PTHR10488; PTHR10488; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Disease mutation; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase; Transit peptide.
FT   TRANSIT       1     37       Mitochondrion. {ECO:0000250}.
FT   CHAIN        38    423       Glycine amidinotransferase,
FT                                mitochondrial.
FT                                /FTId=PRO_0000001206.
FT   ACT_SITE    254    254
FT   ACT_SITE    303    303
FT   ACT_SITE    407    407       Amidino-cysteine intermediate.
FT                                {ECO:0000269|PubMed:9148748}.
FT   MOD_RES      46     46       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      49     49       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     385    385       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ       1     37       MLRVRCLRGGSRGAEAVHYIGSRLGRTLTGWVQRTFQ ->
FT                                MNILK (in isoform 2).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_000235.
FT   VAR_SEQ     388    423       ITTIKVNIRNANSLGGGFHCWTCDVRRRGTLQSYLD -> M
FT                                YNK (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_039871.
FT   VARIANT      23     23       R -> Q (in CCDS3; unknown pathological
FT                                significance; reduces glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs370155767).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076483.
FT   VARIANT      93     93       I -> V (in CCDS3; unknown pathological
FT                                significance; reduces glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs34991226).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076484.
FT   VARIANT     102    102       K -> N (in CCDS3; unknown pathological
FT                                significance; reduces glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs376335787).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076485.
FT   VARIANT     105    105       P -> L (in CCDS3; loss of glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs147804855).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076486.
FT   VARIANT     110    110       Q -> H (in dbSNP:rs1288775).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_020305.
FT   VARIANT     181    181       E -> K (in CCDS3; loss of glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs376982466).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076487.
FT   VARIANT     185    185       A -> P (in CCDS3; decreases glycine
FT                                amidinotransferase activity).
FT                                {ECO:0000269|PubMed:26490222,
FT                                ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076488.
FT   VARIANT     189    189       R -> C (in CCDS3; loss of glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs377578020).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076489.
FT   VARIANT     203    203       Y -> S (in CCDS3; loss of glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs397514709).
FT                                {ECO:0000269|PubMed:23770102,
FT                                ECO:0000269|PubMed:26490222,
FT                                ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_069816.
FT   VARIANT     208    208       A -> T (in CCDS3; loss of glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs374059924).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076490.
FT   VARIANT     231    231       S -> C (decreases glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs202225656).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076491.
FT   VARIANT     234    234       D -> G (decreases glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs146057680).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076492.
FT   VARIANT     282    282       R -> H (in CCDS3; decreases glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs371447931).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076493.
FT   VARIANT     329    329       L -> V (in CCDS3; decreases glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs373802463).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076494.
FT   VARIANT     346    346       P -> L (in CCDS3; decreases glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs142814307).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076495.
FT   VARIANT     413    413       R -> Q (in CCDS3; loss of glycine
FT                                amidinotransferase activity).
FT                                {ECO:0000269|PubMed:23660394,
FT                                ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_071789.
FT   VARIANT     413    413       R -> W (in CCDS3; loss of glycine
FT                                amidinotransferase activity).
FT                                {ECO:0000269|PubMed:23660394,
FT                                ECO:0000269|PubMed:26490222,
FT                                ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_071790.
FT   VARIANT     415    415       R -> Q (in CCDS3; unknown pathological
FT                                significance; reduces glycine
FT                                amidinotransferase activity;
FT                                dbSNP:rs374592247).
FT                                {ECO:0000269|PubMed:27233232}.
FT                                /FTId=VAR_076496.
FT   MUTAGEN     170    170       D->N: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     233    233       E->K: Complete loss of activity; when
FT                                associated with S-407.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     254    254       D->N: Significantly reduced activity.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     303    303       H->V: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     305    305       D->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     322    322       R->E: Significantly reduced activity.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     355    355       S->A: Significantly reduced activity.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     407    407       C->S: Complete loss of activity; when
FT                                associated with K-233.
FT                                {ECO:0000269|PubMed:9266688}.
FT   MUTAGEN     410    410       C->A: No effect on activity.
FT                                {ECO:0000269|PubMed:9266688}.
FT   CONFLICT     98     98       N -> I (in Ref. 3; BAG60595).
FT                                {ECO:0000305}.
FT   CONFLICT    246    246       T -> I (in Ref. 3; BAG60595).
FT                                {ECO:0000305}.
FT   CONFLICT    384    384       E -> G (in Ref. 3; BAG58060).
FT                                {ECO:0000305}.
FT   CONFLICT    395    395       I -> V (in Ref. 3; BAG60595).
FT                                {ECO:0000305}.
FT   STRAND       70     73       {ECO:0000244|PDB:1JDW}.
FT   STRAND       75     80       {ECO:0000244|PDB:1JDW}.
FT   HELIX        93     96       {ECO:0000244|PDB:1JDW}.
FT   HELIX       101    103       {ECO:0000244|PDB:1JDW}.
FT   HELIX       104    110       {ECO:0000244|PDB:1JDW}.
FT   STRAND      113    115       {ECO:0000244|PDB:1JDW}.
FT   HELIX       117    136       {ECO:0000244|PDB:1JDW}.
FT   STRAND      140    142       {ECO:0000244|PDB:1JDW}.
FT   STRAND      152    154       {ECO:0000244|PDB:1JDW}.
FT   STRAND      159    161       {ECO:0000244|PDB:1JDW}.
FT   HELIX       168    171       {ECO:0000244|PDB:1JDW}.
FT   STRAND      172    176       {ECO:0000244|PDB:1JDW}.
FT   STRAND      178    181       {ECO:0000244|PDB:1JDW}.
FT   HELIX       187    189       {ECO:0000244|PDB:1JDW}.
FT   HELIX       192    195       {ECO:0000244|PDB:1JDW}.
FT   HELIX       197    205       {ECO:0000244|PDB:1JDW}.
FT   STRAND      209    212       {ECO:0000244|PDB:1JDW}.
FT   HELIX       220    222       {ECO:0000244|PDB:1JDW}.
FT   HELIX       232    240       {ECO:0000244|PDB:1JDW}.
FT   STRAND      248    250       {ECO:0000244|PDB:1JDW}.
FT   HELIX       255    257       {ECO:0000244|PDB:1JDW}.
FT   STRAND      258    261       {ECO:0000244|PDB:1JDW}.
FT   STRAND      264    267       {ECO:0000244|PDB:1JDW}.
FT   HELIX       275    285       {ECO:0000244|PDB:1JDW}.
FT   TURN        286    288       {ECO:0000244|PDB:1JDW}.
FT   STRAND      290    293       {ECO:0000244|PDB:1JDW}.
FT   STRAND      296    298       {ECO:0000244|PDB:1JDW}.
FT   TURN        305    307       {ECO:0000244|PDB:1JDW}.
FT   STRAND      308    312       {ECO:0000244|PDB:1JDW}.
FT   STRAND      315    318       {ECO:0000244|PDB:1JDW}.
FT   HELIX       327    332       {ECO:0000244|PDB:1JDW}.
FT   STRAND      336    338       {ECO:0000244|PDB:1JDW}.
FT   STRAND      352    354       {ECO:0000244|PDB:1JDW}.
FT   HELIX       356    360       {ECO:0000244|PDB:1JDW}.
FT   STRAND      363    366       {ECO:0000244|PDB:1JDW}.
FT   STRAND      369    373       {ECO:0000244|PDB:1JDW}.
FT   HELIX       377    385       {ECO:0000244|PDB:1JDW}.
FT   STRAND      389    393       {ECO:0000244|PDB:1JDW}.
FT   HELIX       396    399       {ECO:0000244|PDB:1JDW}.
FT   TURN        400    402       {ECO:0000244|PDB:1JDW}.
FT   TURN        405    408       {ECO:0000244|PDB:1JDW}.
FT   STRAND      409    415       {ECO:0000244|PDB:1JDW}.
SQ   SEQUENCE   423 AA;  48455 MW;  5BEF7A8A039B70FB CRC64;
     MLRVRCLRGG SRGAEAVHYI GSRLGRTLTG WVQRTFQSTQ AATASSRNSC AADDKATEPL
     PKDCPVSSYN EWDPLEEVIV GRAENACVPP FTIEVKANTY EKYWPFYQKQ GGHYFPKDHL
     KKAVAEIEEM CNILKTEGVT VRRPDPIDWS LKYKTPDFES TGLYSAMPRD ILIVVGNEII
     EAPMAWRSRF FEYRAYRSII KDYFHRGAKW TTAPKPTMAD ELYNQDYPIH SVEDRHKLAA
     QGKFVTTEFE PCFDAADFIR AGRDIFAQRS QVTNYLGIEW MRRHLAPDYR VHIISFKDPN
     PMHIDATFNI IGPGIVLSNP DRPCHQIDLF KKAGWTIITP PTPIIPDDHP LWMSSKWLSM
     NVLMLDEKRV MVDANEVPIQ KMFEKLGITT IKVNIRNANS LGGGFHCWTC DVRRRGTLQS
     YLD
//
